問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間:2023-09-19

李玫萱
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

120Cases

2016-09-19 - 2019-08-23

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

2023-01-01 - 2023-01-24

Phase III

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Terminated7Sites

2024-04-01 - 2028-01-31

Phase I

Active
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

Terminated1Sites

2021-05-01 - 2023-10-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
  • Condition/Disease

    Pulmonary Fibrosis

  • Test Drug

    BMS-986278

Participate Sites
3Sites

Recruiting3Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus
  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2022-03-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2017-05-15 - 2020-04-09

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
9Sites

Terminated8Sites